Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
暂无分享,去创建一个
Li Ding | Niranjan Nagarajan | Denis Bertrand | Vesteinn Thorsson | David L. Gibbs | Jean Claude Zenklusen | Carolyn M. Hutter | Joshua M. Stuart | Gad Getz | Collin Tokheim | Rehan Akbani | Michael C. Wendl | Katherine A. Hoadley | Antonio Colaprico | Catharina Olsen | Sam Q. Sun | Matthew A. Wyczalkowski | Isidro Cortés-Ciriano | Gordon B. Mills | Matthew H Bailey | Amila Weerasinghe | Lihua Yu | David A. Wheeler | Eduard Porta-Pardo | Reyka Jayasinghe | Andrew D. Cherniack | Benjamin G. Vincent | Chayaporn Suphavilai | V. Thorsson | G. Getz | N. Nagarajan | G. Mills | D. Wheeler | L. Ding | M. Wendl | K. Hoadley | C. Tokheim | Jaegil Kim | R. Akbani | A. Cherniack | I. Cortés-Ciriano | B. Vincent | A. Lazar | Eduard Porta-Pardo | A. Colaprico | C. Hutter | J. Zenklusen | D. Bertrand | Kuan-lin Huang | Catharina Olsen | Chayaporn Suphavilai | Feng Chen | R. Jayasinghe | Lihua Yu | Alison M. Taylor | Alexander J. Lazar | A. Weerasinghe | L. Shmulevich | Jaegil Kim | Feng Chen | Matthew H. Bailey | Kuan-lin Huang | Sam Sun | llya Shmulevich | E. Porta-Pardo
[1] F. Supek,et al. The rules and impact of nonsense-mediated mRNA decay in human cancers , 2016, Nature Genetics.
[2] Ludmila V. Danilova,et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors , 2016, Proceedings of the National Academy of Sciences.
[3] A. Godzik,et al. Mutation Drivers of Immunological Responses to Cancer , 2016, Cancer Immunology Research.
[4] Derek W Wright,et al. Gateways to the FANTOM5 promoter level mammalian expression atlas , 2015, Genome Biology.
[5] Adam B. Olshen,et al. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis , 2009, Bioinform..
[6] Marc E. Lenburg,et al. Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity , 2014, PloS one.
[7] Ashton C. Berger,et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. , 2018, Cancer cell.
[8] Joshua M. Stuart,et al. RADIA: RNA and DNA Integrated Analysis for Somatic Mutation Detection , 2014, PloS one.
[9] L. Attardi,et al. Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.
[10] Ben Lehner,et al. Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types , 2015, Molecular systems biology.
[11] D. Bates,et al. Hallmarks of alternative splicing in cancer , 2014, Oncogene.
[12] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[13] Michael T. Zimmermann,et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas , 2018, Cell reports.
[14] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[15] Eunhee Kim,et al. RNA splicing factors as oncoproteins and tumour suppressors , 2016, Nature Reviews Cancer.
[16] Kern Rei Chng,et al. Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles , 2015, Nucleic acids research.
[17] M. Nielsen,et al. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.
[18] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[19] Steven J. M. Jones,et al. Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.
[20] A. Bashashati,et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.
[21] Matthew D. Wilkerson,et al. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..
[22] Peter W. Laird,et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.
[23] F. Stossi,et al. Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming , 2017, Nature.
[24] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[25] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[26] Ken Chen,et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..
[27] Li Ding,et al. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers , 2018, Cell reports.
[28] Su-In Lee,et al. The Proteomic Landscape of Triple-Negative Breast Cancer. , 2015, Cell reports.
[29] Stephen R. Piccolo,et al. A cloud-based workflow to quantify transcript-expression levels in public cancer compendia , 2016, Scientific Reports.
[30] David Tamborero,et al. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..
[31] Li Ding,et al. MIRMMR: binary classification of microsatellite instability using methylation and mutations , 2017, Bioinform..
[32] Gianluca Bontempi,et al. Moonlight: a tool for biological interpretation and driver genes discovery , 2018, bioRxiv.
[33] Rui-Ru Ji,et al. An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.
[34] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[35] A. Godzik,et al. Comparison of algorithms for the detection of cancer drivers at subgene resolution , 2017, Nature Methods.
[36] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[37] Axel Benner,et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer , 2009, Breast Cancer Research and Treatment.
[38] Gianluca Bontempi,et al. TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages , 2016, F1000Research.
[39] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[40] Ping Zhu,et al. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. , 2018, Cell reports.
[41] Thomas D. Wu,et al. A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.
[42] Guey-Shin Wang,et al. Splicing in disease: disruption of the splicing code and the decoding machinery , 2007, Nature Reviews Genetics.
[43] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[44] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[45] Matthew B. Callaway,et al. MuSiC: Identifying mutational significance in cancer genomes , 2012, Genome research.
[46] P. A. Futreal,et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data , 2016, Genome Biology.
[47] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[48] Benjamin Schubert,et al. OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..
[49] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[50] Steven J. M. Jones,et al. The Immune Landscape of Cancer , 2018, Immunity.
[51] Steve Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[52] Rajarsi R. Gupta,et al. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. , 2018, Cell reports.
[53] A. Gonzalez-Perez,et al. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations , 2016, Genome Biology.
[54] Gary D Bader,et al. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers , 2013 .
[55] Derek Y. Chiang,et al. MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery , 2010, Nucleic acids research.
[56] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[57] Matthew A. Wyczalkowski,et al. Divergent viral presentation among human tumors and adjacent normal tissues , 2016, Scientific Reports.
[58] A. Scorilas,et al. A new tumor suppressor role for the Notch pathway in bladder cancer , 2014, Nature Medicine.
[59] L. Riboni,et al. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration , 2008, Journal of Neuro-Oncology.
[60] Adam Godzik,et al. e-Driver: a novel method to identify protein regions driving cancer , 2014, Bioinform..
[61] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[62] Ash A. Alizadeh,et al. Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.
[63] Luca Scrucca,et al. mclust 5: Clustering, Classification and Density Estimation Using Gaussian Finite Mixture Models , 2016, R J..
[64] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[65] Alex Arenas,et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules , 2010, BMC Cancer.
[66] Andrew H. Beck,et al. The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma , 2009, Clinical Cancer Research.
[67] C. Yau,et al. A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay , 2017, Nature Communications.
[68] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[69] E. Birney,et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.
[70] Benjamin J. Raphael,et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.
[71] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[72] J. Costello,et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.
[73] P. Lønning,et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases , 2016, International journal of cancer.
[74] M. Stratton,et al. High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.
[75] Markus K. Muellner,et al. Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity , 2016, PLoS genetics.
[76] T. Cedena,et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. , 2014, Blood.
[77] Christopher D. Brown,et al. Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression , 2017, PLoS genetics.
[78] K. Kinzler,et al. Evaluating the evaluation of cancer driver genes , 2016, Proceedings of the National Academy of Sciences.
[79] Gianluca Bontempi,et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.
[80] B. Taylor,et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma , 2016, Nature Genetics.
[81] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[82] M. Miyazaki,et al. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags , 2016, British Journal of Cancer.
[83] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[84] Knut Reinert,et al. Fast and accurate read mapping with approximate seeds and multiple backtracking , 2012, Nucleic acids research.
[85] A. Drilon,et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.
[86] Li Ding,et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.
[87] Li Ding,et al. Protein-structure-guided discovery of functional mutations across 19 cancer types , 2016, Nature Genetics.
[88] Kai Ye,et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..
[89] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[90] Li Ding,et al. Patterns and functional implications of rare germline variants across 12 cancer types , 2015, Nature Communications.
[91] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[92] Steven J. M. Jones,et al. Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.
[93] Benjamin J. Raphael,et al. A weighted exact test for mutually exclusive mutations in cancer , 2016, Bioinform..
[94] Matthew A. Wyczalkowski,et al. Systematic Analysis of Splice-Site-Creating Mutations in Cancer , 2018, Cell reports.
[95] Benjamin J. Raphael,et al. GenomeVIP: a cloud platform for genomic variant discovery and interpretation , 2017, Genome research.
[96] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[97] Junjie Hou,et al. Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation , 2017, Oncotarget.
[98] Benjamin J. Raphael,et al. Integrated Analysis of Germline and Somatic Variants in Ovarian Cancer , 2014, Nature Communications.
[99] Mariano J. Alvarez,et al. Network-based inference of protein activity helps functionalize the genetic landscape of cancer , 2016, Nature Genetics.
[100] Wenjun Chang,et al. Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer , 2017, Science Signaling.